Levoethin (Ethinylestradiol, Levonorgestrel)

The estrogen (ethinylestradiol) and progestin (levonorgestrel) suppress the release of luteinising hormone and follicle‑stimulating hormone, which blocks ovulation. The progestin also thickens cervical mucus and alters the endometrium, creating an environment that reduces the chance of fertilisation and implantation.

The specific dosing regimen is determined by the prescribing clinician. Typically, Levoethin is taken as a daily tablet for a 21‑day active phase followed by a 7‑day placebo phase, but the exact schedule and strength are set by the healthcare professional based on individual needs.

Levoethin is not intended for use during pregnancy; if pregnancy occurs, the product should be discontinued immediately. Limited data exist for breastfeeding, and while some clinicians may allow use after the first postpartum weeks, it should only be taken under medical advice.

To order Levoethin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levoethin offers efficacy comparable to other combined estrogen‑progestin pills. Differences lie mainly in the specific hormone doses, which can influence side‑effect profiles such as weight change, mood variation, or risk of breakthrough bleeding. Clinicians choose based on individual patient risk factors and tolerability.

Store Levoethin at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Levoethin is taken orally as a tablet once daily, preferably at the same time each day. It may be taken with or without food, but consistent timing helps maintain steady hormone levels and maximises contraceptive effectiveness.

The most serious risks include thromboembolic events such as deep‑vein thrombosis and pulmonary embolism, as well as rare but severe allergic reactions like anaphylaxis. Women with a history of clotting disorders, certain cancers, or uncontrolled hypertension should discuss these risks with their clinician.

Levoethin is contraindicated in women who have a history of thromboembolic disease, estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or who are smokers over 35 years old. It should also be avoided during pregnancy and in individuals with known hypersensitivity to any component of the product.